Dashboard
Manage Tickers

FULCFulcrum Therapeutics, Inc.

Nasdaq fulcrumtx.com


$ 3.18 $ 0.00 (0 %)    

Monday, 16-Sep-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 3.18
$ 3.18
$ 3.16 x 600
-- x --
$ 3.12 - $ 3.38
$ 2.87 - $ 13.70
2,922,930
na
198.43M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-03-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-04-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-13-2020 03-31-2020 10-Q
19 03-05-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-26-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-downgrades-fulcrum-therapeutics-to-sector-perform-lowers-price-target-to-4
RBC Capital Downgrades Fulcrum Therapeutic...
09/13/2024 13:36:04

RBC Capital analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Sector Perform and lowers...

breaking-down-fulcrum-therapeutics-7-analysts-share-their-views
Breaking Down Fulcrum Therapeutics: 7 Anal...
09/13/2024 13:00:33

hc-wainwright--co-downgrades-fulcrum-therapeutics-to-neutral-lowers-price-target-to-4
HC Wainwright & Co. Downgrades Fulcrum The...
09/13/2024 11:39:41

HC Wainwright & Co. analyst Andrew Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the...

leerink-partners-downgrades-fulcrum-therapeutics-to-market-perform-announces-4-price-target
Leerink Partners Downgrades Fulcrum Therap...
09/12/2024 19:35:11

Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and...

dow-surges-over-100-points-modivcare-shares-plummet
Dow Surges Over 100 Points; ModivCare Shar...
09/12/2024 18:01:18

b-of-a-securities-downgrades-fulcrum-therapeutics-to-underperform-lowers-price-target-to-2
B of A Securities Downgrades Fulcrum Thera...
09/12/2024 17:55:03

B of A Securities analyst Tazeen Ahmad downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Underperform and lowers...

stifel-downgrades-fulcrum-therapeutics-to-hold-lowers-price-target-to-3
Stifel Downgrades Fulcrum Therapeutics to ...
09/12/2024 16:50:09

Stifel analyst Dae Gon Ha downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $2...

crude-oil-surges-3-kroger-posts-upbeat-earnings
Crude Oil Surges 3%; Kroger Posts Upbeat E...
09/12/2024 16:10:01

fulcrum-therapeutics-suspends-rare-muscular-disease-candidate-after-disappointing-data-from-pivotal-trial
Fulcrum Therapeutics Suspends Rare Muscula...
09/12/2024 15:32:22

Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The c...

cantor-fitzgerald-downgrades-fulcrum-therapeutics-to-neutral
Cantor Fitzgerald Downgrades Fulcrum Thera...
09/12/2024 15:19:45

Cantor Fitzgerald analyst Kristen Kluska downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Neutral.

us-stocks-mixed-producer-prices-increase-in-august
US Stocks Mixed; Producer Prices Increase ...
09/12/2024 14:23:57

Core News & Articles
Market-Moving News for September 12th
09/12/2024 12:08:39

CSBR: 59% | Champions Oncology shares are trading higher after the company reported better-than-expected Q1 financial results. ...

fulcrum-to-suspend-future-losmapimod-development
Fulcrum To Suspend Future Losmapimod Devel...
09/12/2024 10:57:38

fulcrum-therapeutics-phase-3-reach-trial-of-losmapimod-in-facioscapulohumeral-muscular-dystrophy-did-not-achieve-its-primary-endpoint-of-change-from-baseline-in-relative-surface-area-with-losmapimod-compared-to-placebo-in-addition-secondary-endpoints-did-not-achieve-nominal-statistical-significance
Fulcrum Therapeutics' Phase 3 REACH Trial ...
09/12/2024 10:57:03

fulcrum-therapeutics-upgraded-bofa-debates-pivotal-study-success-for-losmapimod-in-rare-genetic-muscle-disease
Fulcrum Therapeutics Upgraded: BofA Debate...
09/09/2024 18:28:05

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...

b-of-a-securities-upgrades-fulcrum-therapeutics-to-neutral-raises-price-target-to-10
B of A Securities Upgrades Fulcrum Therape...
09/09/2024 11:42:17

B of A Securities analyst Tazeen Ahmad upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Underperform to Neutral and raises t...

8-health-care-stocks-with-whale-alerts-in-todays-session
8 Health Care Stocks With Whale Alerts In ...
08/01/2024 17:35:24

hc-wainwright--co-reiterates-buy-on-fulcrum-therapeutics-maintains-17-price-target
HC Wainwright & Co. Reiterates Buy on Fulc...
08/01/2024 13:14:09

HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...

fulcrum-therapeutics-q2-eps-totals-087-compared-with-038-loss-yoy-company-exits-quarter-with-cash-and-equivalents-worth-2738m
Fulcrum Therapeutics Q2 EPS Totals $0.87 C...
07/31/2024 11:08:26

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly earnings of $0.87 per share his is a 328.95 percent increase over losses ...

top-3-health-care-stocks-that-should-keep-you-up-at-night-this-quarter
Top 3 Health Care Stocks That Should Keep ...
07/16/2024 12:16:01

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION